Analysts Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Price Target at $7.25

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have earned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $7.25.

Several equities analysts have recently commented on PRQR shares. Weiss Ratings upgraded ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 8th. Wall Street Zen lowered ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Oppenheimer started coverage on ProQR Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $9.00 price target on the stock. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. Finally, Chardan Capital restated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday, April 9th.

Hedge Funds Weigh In On ProQR Therapeutics

Institutional investors have recently made changes to their positions in the company. Osaic Holdings Inc. increased its stake in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 4,500 shares during the period. Guggenheim Capital LLC bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $35,000. Moody Lynn & Lieberson LLC bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $50,000. Invesco Ltd. bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $51,000. Finally, Axiom Investment Management LLC bought a new stake in ProQR Therapeutics during the first quarter valued at about $53,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

NASDAQ PRQR opened at $1.89 on Monday. The company’s 50-day moving average price is $1.62 and its 200-day moving average price is $1.72. The stock has a market cap of $199.13 million, a PE ratio of -3.78 and a beta of 0.07. ProQR Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15). The firm had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. As a group, sell-side analysts forecast that ProQR Therapeutics will post -0.57 earnings per share for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.